医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s to Release Q4 and Full Year FY13 Results on May 14, 2013

2013年04月30日 PM01:40
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY) will announce results for the Fourth Quarter and Full year ended March 31, 2013 on Tuesday, May 14, 2013 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com

Summary of Events

Event       Date and Time (IST)       Medium
Release of financial results       May 14th, after the Board Meeting      

Email, Media, Company website, Business Wire

Earnings Call      

May 14th, 6.30 PM IST / 9:00 AM EDT

      Hosted by the Company

(Details below)

Webcast of Earnings Call       May 14th, 6.30 PM IST / 9.00 AM EDT through May 19th, 2013      

URL available on Company’s website,

www.drreddys.com

Transcripts of the Earnings call       Will be available on the Company’s website      

URL available on Company’s website, www.drreddys.com

           

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance.

Conference Dial-In Numbers
Primary Number:     +91 22 6629 0356
Secondary Number:     +91 22 3065 0136
The numbers listed above are universally accessible from all networks and all countries.
Local Access Number:     6000 1221
Available in – Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada

Accessible from all major carriers except BSNL/MTNL.

3940 3977

Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune

Accessible from all carriers.

International Toll Free Number:     USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

   

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through May 19th, 2013. For play back dial in phone No: 022 3065 1212 and ID: 375#.

Transcript

The transcript of the earnings call will also be available on the Company’s website.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets.

For more information, log on to: www.drreddys.com

*EDT- Eastern Daylight Saving Time

CONTACT

Dr. Reddy’s Laboratories Ltd.
Investor Relations:
Kedar
Upadhye, +91 40 66834297
kedaru@drreddys.com
or
Saunak
Savla, +91 40 49002135
saunaks@drreddys.com
or
Milan
Kalawadia (USA), +1 908-203-4931
mkalawadia@drreddys.com

同じカテゴリーの記事 

  • 日本天皇陛下和皇后出席2024年度日本奖颁奖典礼
  • Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions
  • ReNAgade Therapeutics宣布在ASGCT第27届年会上发表演讲
  • ReNAgade TherapeuticsがASGCT第27回年次総会でのプレゼンテーションの内容を発表
  • BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer